

CITATION REPORT

List of articles citing

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design

DOI: 10.1128/AAC.02154-17

Antimicrobial Agents and Chemotherapy, 2018, 62, .

Source: <https://exaly.com/paper-pdf/85892035/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
43	Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 14, 58-64	3.4	45
42	Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against <i>Candida albicans</i> and <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	16
41	Pharmacodynamic Evaluation of Rezafungin (CD101) against <i>Candida auris</i> in the Neutropenic Mouse Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	38
40	Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. <i>Drugs and Aging</i> , 2018 , 35, 781-789	4.7	10
39	Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018 , 5, 300-326	3.9	57
38	Extended-Interval Dosing of Rezafungin against Azole-Resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	14
37	Determination of Pharmacodynamic Target Exposures for Rezafungin against <i>Candida tropicalis</i> and <i>Candida dubliniensis</i> in the Neutropenic Mouse Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	8
36	Bioactive Peptides Against Fungal Biofilms. <i>Frontiers in Microbiology</i> , 2019 , 10, 2169	5.7	31
35	Extended Dosing Regimens for Fungal Prophylaxis. <i>Clinical Microbiology Reviews</i> , 2019 , 32,	34	10
34	Fungal Cell Wall: Emerging Antifungals and Drug Resistance. <i>Frontiers in Microbiology</i> , 2019 , 10, 2573	5.7	62
33	Cell Wall-Modifying Antifungal Drugs. <i>Current Topics in Microbiology and Immunology</i> , 2020 , 425, 255-275	3.3	6
32	Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy. <i>Pharmacology Research and Perspectives</i> , 2019 , 7, e00546	2.1	19
31	Antifungal drugs: New insights in research & development. <i>Pharmacology & Therapeutics</i> , 2019 , 195, 21-38	3.9	54
30	Hope on the Horizon: Novel Fungal Treatments in Development. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa016	1	70
29	Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 12429-12459	8.3	15
28	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3647-e3655	11.6	22
27	Elevated Vacuolar Uptake of Fluorescently Labeled Antifungal Drug Caspofungin Predicts Echinocandin Resistance in Pathogenic Yeast. <i>ACS Central Science</i> , 2020 , 6, 1698-1712	16.8	8

26	Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins. <i>Current Fungal Infection Reports</i> , 2020 , 14, 258-267	1.4	0
25	Oral Candidiasis: A Disease of Opportunity. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	81
24	Extrapolating Antifungal Animal Data to Humans - Is it reliable?. <i>Current Fungal Infection Reports</i> , 2020 , 14, 50-62	1.4	4
23	Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	20
22	Natural products and derivatives as human drugs. 2021 , 59-74		
21	Echinocandins. 2021 , 438-448		
20	Rezafungin: a novel antifungal for the treatment of invasive candidiasis. <i>Future Microbiology</i> , 2021 , 16, 27-36	2.9	6
19	Novel antifungal agents in clinical trials.. <i>F1000Research</i> , 2021 , 10, 507	3.6	3
18	Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Infection: A Case Report.. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab431	1	1
17	The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	3
16	Antifungal Pipeline. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 732223	5.9	4
15	Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	8
14	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. <i>Drugs</i> , 2021 , 81, 1703-1729	12.1	25
13	Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 ,	3.2	2
12	Optimization of Dosage Regimen of Rezafungin against <i>Candida spp.</i>Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Pharmacology & Pharmacy</i> , 2020 , 11, 79-84	0.3	
11	Novel antifungal agents in clinical trials. <i>F1000Research</i> , 10, 507	3.6	1
10	Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 759408	5.9	4
9	Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).. <i>Journal of Clinical Microbiology</i> , 2022 , e0244921	9.7	0

8	Echinocandins Localized to the Target-Harboring Cell Surface Are Not Degraded but Those Entering the Vacuole Are.. <i>ACS Chemical Biology</i> , 2022 ,	4.9	0
7	Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action. <i>Expert Opinion on Investigational Drugs</i> ,	5.9	2
6	Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> ,	5.1	0
5	Development and research progress of anti-drug resistant fungal drugs. 2022 , 15, 986-1000		1
4	Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin.		0
3	Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients. 2022 , 27, 235-242		0
2	Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician. Volume 16, 1087-1097		1
1	Analysis of Candida Antifungal Resistance Using Animal Infection Models. 2023 , 225-238		0